Evidence map›Paper›PMID 41392987›Full record

ArticleThe Journal of clinical investigation2025

Interlocking host and viral cis-regulatory networks drive Merkel cell carcinoma.

Lingling Miao, David Milewski, Amy Coxon, Tara Gelb, Khalid A Garman, Jadon Porch, Arushi Khanna, Loren Collado, Natasha T Hill, Kenneth Daily and 19 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Lingling MiaoDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
David MilewskiGenetics Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
Amy CoxonDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Tara GelbDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Khalid A GarmanDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Jadon PorchDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
Arushi KhannaDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
Loren ColladoDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Natasha T HillDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Kenneth DailyDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Serena VilasiDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Danielle ReedDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Tiffany AlexanderDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.
Gabriel J StarrettLaboratory of Cellular Oncology, NCI, NIH, Bethesda, Maryland, USA.
Maharshi ChakrabortyAxiotl, Cleveland, Ohio, USA.
Young SongGenetics Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
Rachel ChoiGenetics Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
Vineela GangalapudiGenetics Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
Josiah SeamanDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
Andrew MortonDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
Klaus J BusamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Christopher R VakocCold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.
Daniel J UrbanDivision of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, Rockville, Maryland, USA.
Min ShenDivision of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, Rockville, Maryland, USA.
Matthew D HallDivision of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, Rockville, Maryland, USA.
Richard SallariAxiotl, Cleveland, Ohio, USA.
Javed KhanGenetics Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
Berkley E GryderGenetics Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
Isaac BrownellDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Molecular pathogenesis and therapy innovation for Merkel cell carcinomaZIAAR041222 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI BROWNELL, ISAAC · 2022 to 2025
$4.0M
Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate CancerR01CA291963 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Berkley E Gryder · 2024 to 2026
$2.8M
Intramural NIH HHS ZIA AR041222NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA291963
6 · The paper itself

Abstract

Over 15% of cancers worldwide are caused by viruses. Merkel cell polyomavirus (MCPyV) is the most recently discovered human oncovirus and is the only polyomavirus that drives malignant tumors in humans. Here, we show that MCPyV+ Merkel cell carcinoma is defined by neuroendocrine-lineage core regulatory (CR) transcription factors (TFs) (ATOH1, INSM1, ISL1, LHX3, POU4F3, and SOX2) that were essential for tumor survival and that co-bound chromatin with the viral small T antigen at super enhancers. Moreover, MCPyV integration sites were enriched at these neuroendocrine super enhancers. We further discovered that the MCPyV noncoding control region contained a homeodomain binding motif absent in other polyomaviruses that bound ISL1 and LHX3 and depended on them for T antigen expression. To therapeutically target the CR factors, we used histone deacetylase (HDAC) inhibitors to collapse the chromatin architecture and induce topological blurring of superenhancer loops, abrogating core TF expression and halting tumor growth. To our knowledge, our study presents the first example of oncogenic cross-regulation between viral and human epigenomic circuitry to generate interlocking and essential transcriptional feedback circuits that explain why MCPyV causes neuroendocrine cancer and represent a tumor dependency that can be targeted therapeutically.

Indexed as

Carcinoma, Merkel CellGene Regulatory NetworksMerkel cell polyomavirusNeoplasm ProteinsPolyomavirus InfectionsSkin NeoplasmsTumor Virus InfectionsAnimalsAntigens, Viral, TumorCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceTranscription FactorsAntigens, Viral, TumorNeoplasm ProteinsTranscription FactorsDermatologyEpigeneticsOncologySkin cancer

Identifiers

PMID41392987
PMCPMC12700541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.